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Abstract
Background: Heroin dependence is a debilitating psychiatric disorder with complex inheritance. Since the dopaminergic
system has a key role in rewarding mechanism of the brain, which is directly or indirectly targeted by most drugs of abuse,
we focus on the effects and interactions among dopaminergic gene variants.
Objective: To study the potential association between allelic variants of dopamine D2 receptor (DRD2), ANKK1 (ankyrin
repeat and kinase domain containing 1), dopamine D4 receptor (DRD4), catechol-O-methyl transferase (COMT) and
dopamine transporter (SLC6A3) genes and heroin dependence in Hungarian patients.
Methods: 303 heroin dependent subjects and 555 healthy controls were genotyped for 7 single nucleotide polymorphisms
(SNPs) rs4680 of the COMT gene; rs1079597 and rs1800498 of the DRD2 gene; rs1800497 of the ANKK1 gene; rs1800955,
rs936462 and rs747302 of the DRD4 gene. Four variable number of tandem repeats (VNTRs) were also genotyped: 120 bp
duplication and 48 bp VNTR in exon 3 of DRD4 and 40 bp VNTR and intron 8 VNTR of SLC6A3. We also perform a
multivariate analysis of associations using Bayesian networks in Bayesian multilevel analysis (BN-BMLA).
Findings and conclusions: In single marker analysis the TaqIA (rs1800497) and TaqIB (rs1079597) variants were associated
with heroin dependence. Moreover, –521 C/T SNP (rs1800955) of the DRD4 gene showed nominal association with a
possible protective effect of the C allele. After applying the Bonferroni correction TaqIB was still significant suggesting that
the minor (A) allele of the TaqIB SNP is a risk component in the genetic background of heroin dependence. The findings of
the additional multiple marker analysis are consistent with the results of the single marker analysis, but this method was
able to reveal an indirect effect of a promoter polymorphism (rs936462) of the DRD4 gene and this effect is mediated
through the –521 C/T (rs1800955) polymorphism in the promoter.
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Introduction
Substance abuse presents a major health and social problem
worldwide. It is broadly accepted that multiple genetic and
environmental risk factors and their interactions may contribute to
the development of drug addiction. However, at present, little is
known about the exact nature of these genetic components.
Family-, twin- and adoption studies have shown that the
heritability of alcoholism is around 40–60% [1], other studies
found similar heritability values in the context of substance use
[2,3,4]. Neurobiological models accentuate the key role of the
brain’s reward system via the dopaminergic mesocorticolimbic
pathway, which is modulated by complex, mutual interactions
with other stimulatory and inhibitory neurotransmitter systems.
Various drugs of abuse act at different points of these systems, but
eventually they all converge into elevated levels of dopamine
released in the nucleus accumbens [5,6].
The dopaminergic system has a key role in the rewarding and
reinforcing mechanisms of the brain [7], which is the most likely
target of drug abuse. Dopamine can be released as a result of using
drugs such as nicotine, cocaine, cannabis and opiates. After heroin
is converted into morphine, it acts as a m-opioid receptor agonist.
Ligand binding decreases the release of GABA from interneurons,
thus reducing the inhibitory effect of GABA on dopaminergic
neurons and as a result a sustained synaptic level of dopamine can
be observed, which is perceived as euphoria [8]. As interindividual
differences in the function of the mesocorticolimbic dopaminergic
reward system have an influence on the drug-induced response of
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the body, genetic variants of the neurotransmitter systems involved
in the reward system - especially dopamine - are the most likely
candidate genes of drug addiction.
Genetic polymorphisms of the dopaminergic system include
single nucleotide polymorphisms (SNPs) and length polymor-
phisms of the receptors, transporters and metabolizing enzymes.
One of the most widely studied candidate genes is the dopamine
D2 receptor (DRD2) characterized previously with TaqIA, TaqIB,
and TaqID SNPs based on restriction digestion of this region with
the TaqI enzyme. Early studies indicated the A1 allele of TaqIA as
a risk factor of substance abuse, alcoholism [9] and heroin
dependence [10], but some studies have failed to replicate these
findings [11,12]. Later it turned out that the TaqIA restriction
fragment length polymorphism (RFLP) is located approximately
10 kilobases downstream from the DRD2 gene, in exon 8 of the
ANKK1 (ankyrin repeat and kinase domain containing 1) gene
[13], which is a member of the serine/threonine kinase family.
The TaqIA polymorphism, causing an amino acid change in
ANKK1 (Glu713Lys), seems to have a significant effect on the
specificity of substrate binding. The protein product of the
ANKK1 gene was considered as a negative regulator of the NF-
kB (Nuclear Factor-KappaB) transcription factor [14]. Moreover,
the expression level of NF-kB-regulated genes was shown to be
altered by TaqIA variants in an in vitro luciferase system [15].
Since DRD2 is regulated by NF-kB [16,17] it could be assumed
that this ANKK1 variant can indirectly affect DRD2 receptor
density. It is also possible, however, that the TaqIA SNP is only a
marker of other functional DRD2 variants associated with
addiction, such as the strongly linked TaqIB [18].
An interesting hypothesis has arisen from the possible role of
decreased dopamine receptor density resulting in Reward
Deficiency Syndrome [5]. It is well known that under normal
conditions dopamine is released into the synapse, binds to
dopamine receptors, inducing euphoria and stress reduction.
Reward Deficiency Syndrome is characterized by a lower basal
dopamine level due to insufficient receptor capacity resulting in a
need of a certain amount of dopamine to feel good (this could be
achieved by rewarding experiences such as drugs, gambling,
alcohol, etc.). Studies on animal models further underline the role
of DRD2 in drug addiction as the rewarding effects of opiates were
found absent in mice lacking the D2 receptor gene [19,20].
Another widely studied polymorphic dopamine receptor is the
dopamine D4 receptor gene (DRD4) with more than 200 SNPs
and several VNTRs. The 48 bp repeat polymorphism is an exonic
variant (48 bp VNTR) changing the length of the third
intracellular loop of the receptor with a possible effect on signaling
efficiency [21]. The DRD4 7 repeat allele seems to show decreased
sensitivity to dopamine compared with the 4 repeat allele [22] and
according to recent neurobiological findings it does not form
heteromers with D2 receptors in the striatum [23]. Carriers of the
‘‘long’’ allele possessing 7 repeats of the 48 bp sequence were
shown to have higher novelty seeking scores compared to non-
carriers assessed by psychological questionnaires [24,25,26,27],
however, replication studies were contradictory (for a review see
Kluger et al., 2002 [28]). It has also been shown that individuals
with high novelty seeking scores are prone to increased substance
use [29,30,31]. Therefore, the DRD4 long allele was considered as
a predictive marker of various addictive behaviors. This hypothesis
was supported in alcoholics [32], heroin dependent patients [33]
and individuals with eating disorders [34], but subsequent
replications were also contradictory (for a review see McGeary,
2009 [35]). One of the possible reasons for unsuccessful replication
studies might be the high genetic variability of the DRD4 gene
including other functional variants beside the exonic 48 bp
VNTR. Molecular effect of DRD4 promoter region polymor-
phisms (120 bp duplication, 2615 A/G, 2616 C/G and 2521
C/T) has been studied by others, as well as in our laboratory
[36,37,38,39,40,41]. Furthermore we previously described a novel
SNP 2615 A/G generating a source of possible misgenotyping of
the adjacent SNP 2616 C/G by conventional methods [42].
Catechol-O-methyl transferase (COMT) plays an important
role in the regulation of synaptic dopamine levels since it is
responsible for the catabolism of dopamine. The Val158Met exonic
SNP (rs4680) of COMT is considered to influence enzyme activity
[43], making this polymorphism a possible marker of genetic
predisposition to addiction [44].
The dopamine transporter is responsible for the re-uptake of
dopamine from the synapse in midbrain dopaminergic neurons
[45], playing a key role in the homeostatic regulation of
dopaminergic neurotransmission. Genetic variants of the dopa-
mine transporter gene (SLC6A3 or commonly DAT) have also
been implicated in human mental disorders such as parkinsonism,
Tourette syndrome, and substance abuse [46].
Here, we present a combined analysis of the key candidate
polymorphisms in the dopaminergic system as possible risk factors
for heroin dependence in a case-control study of Central European
descent (Hungarian). Moreover, we focus on the interactions
among these genetic variants using Bayesian networks in Bayesian
multilevel analysis (for previous applications of BN-BMLA, see
[47,48,49,50]).
Materials and Methods
1. Subjects
Cases. The initial cohort consisted of 307 heroin dependent
patients. Four subjects suffering from a major psychiatric disorder
(schizophrenia and major depression) with possible involvement of
the studied neurotransmitter systems were excluded from the
study. All subjects were unrelated with Hungarian origin. The
final sample included 303 heroin dependent patients (211 (69.6%)
males and 92 females (30.4%)) from three centers, the National
Institute of Psychiatry and Neurology, Budapest; the Dr.
Farkasinszky Tere´zia Youth Drug Centre, Szeged and the Nyı´ro˝
Gyula Hospital Drug Outpatient and Prevention Center, Buda-
pest.
Diagnosis was made based on DSM-IV criteria (American
Psychiatric Association, 1994). The age of subjects at diagnosis was
15–70 years (mean age = 28.64 years 66.448). All patients with
heroin dependence reported heroin as their primary drug of
choice. Non-opioid substance use (such as alcohol, cocaine,
marijuana, amphetamine, LSD, benzodiazepine, etc.) was not an
exclusion criterion since heroin dependent patients frequently use
alcohol, cannabis or cocaine as secondary drugs.
Controls. Genotype data of 555 sexually matched healthy
Hungarian control subjects (386 [69.5%] males and 169 females
[30.5%]) was used to construct a large normative sample for
determination of control genotype and allele frequencies. These
subjects did not suffer from psychiatric disorders. Nicotine
dependence was not an exclusion criterion from the control group.
The research protocol has been approved by the Hungarian
National Ethical Committee (TUKEB), as well as the Ethical
Board of Semmelweis University and the Institute of Psychology,
Eo¨tvo¨s Lora´nd University. All participants were over the age of 18
at the time of inclusion in the study. All participants provided
written informed consent.
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2. Genotyping
A non-invasive DNA sampling method was used to obtain the
sufficient quantity of buccal cells (method is described elsewhere
[51]). Genomic DNA was isolated from buccal swabs [51] or
mouthwash using the DNA-purification kit obtained from Gentra
(Minneapolis, US) and approximately 1 ng DNA was used as
template for each of the tested polymorphisms, performed as
described earlier (DRD4 gene: 2521 C/T SNP [52], 120 bp
duplication [40], DRD4 VNTR [53]). The 2521 C/T polymor-
phism was determined by two independent methods using a newly
designed primer pair [54], and only genotypes with identical
results were accepted. Using this improved method the genotype
distribution of the control population corresponds to the Hardy-
Weinberg equilibrium (see Table 1).
Genotyping methods included restriction fragment length
polymorphism, allele-specific amplification and real-time PCR.
Genotyping procedures for the DRD2/ANKK1 TaqIA
(rs1800497), the DRD2 TaqIB (rs1079597) and TaqID
(rs1800498), the SLC6A3 40 bp VNTR in the 39 untranslated
region, the DRD4 48 bp VNTR in exon 3 and 120 bp duplication
in the promoter region, and the allele-specific amplifications of the
DRD4 2616 C/G (rs747302), 2615 A/G (rs936462), 2521 C/T
(rs1800955) and COMT Val158Met (rs4680) were carried out
using published protocols [53,55,56,57,58,59,60]. The genotype-
phenotype data underlying the present study was deposited in the
Dryad Data Repository (www.datadryad.org) at http://dx.doi.
org/10.5061/dryad.975 kk.
2.1. Restriction fragment length polymorphism. 1 mM
of each primer was used to carry out the amplification (method
developed by Percy et. al. [52]). In the case of COMT the forward
(59-CTC ATC ACC ATC GAG ATC AA-39) and reverse primers
(59-CCT TTT TCC AGG TCT GAC AA-39) were used with 1x
Buffer and Q-solution (Qiagen); 200 mM dATP, dCTP, dGTP
and dTTP; 0.1 U HotStarTaq DNA polymerase and 5 ng
genomic DNA (10 mL final volume). Thermocycling conditions:
95uC for 15 minutes, 40 cycles of 94uC, 30 sec denaturation at
52uC, 30 sec annealing and 1 min at 72uC for extension and
finally a 10-minute polymerization at 72uC. Digestion was carried
Table 1. Results of the case-control analysis.
Gene Marker Genotype
Control
(N)
Control
(%) HWE
Case
(N)
Case
(%)
HWE
p-value
Dominant model
p-value
Dominant model OR
(95% CI)
COMT Val158Met GG 125 22.5% 0.99 75 24.8% 0.993 0.329 1.17 (0.85–1.62)
rs4680 AG 275 49.6% 152 50.4%
AA 155 27.9% 75 24.8%
ANKK1 TaqIA TT 17 3.2% 0.912 18 6.1% 0.757 0.009 1.49 (1.11–2.00)
rs1800497 CT 148 27.9% 100 34.0%
CC 366 68.9% 176 59.9%
DRD2 TaqIB AA 12 2.3% 0.833 13 4.6% 0.869 0.003* 1.61 (1.18–2.21)
rs1079597 AG 123 23.5% 88 31.3%
GG 388 74.2% 180 64.1%
TaqID CC 78 15.8% 0.989 56 19.4% 0.898 0.381 1.15 (0.84–1.56)
rs1800498 CT 239 48.2% 138 47.8%
TT 178 36.0% 95 32.8%
DRD4 2521 C/T CC 111 21.0% 0.989 61 20.2% 0.282 0.007 0.66 (0.48–0.89)
rs1800955 CT 278 52.6% 134 44.4%
TT 140 26.4% 107 35.4%
2615 A/G GG 4 0.8% 0.18 5 1.7% 0.731 0.302 1.18 (0.86–1.63)
rs936462 AG 128 24.2% 80 26.6%
AA 395 75.0% 215 71.7%
2616 C/G GG 120 22.5% 0.927 62 20.5% 0.307 0.610 1.09 (0.79–1.50)
rs747302 CG 271 50.7% 164 54.3%
CC 143 26.8% 76 25.2%
120dup 1-absent 392 70.9% 0.974 211 69.6% 0.851 0.702 1.06 (0.78–1.44)
1-present 161 29.1% 92 30.4%
48 bp VNTR 7-absent 337 62.3% 0.219 195 64.8% 0.977 0.472 0.90 (0.67–1.20)
7-present 204 37.7% 106 35.2%
SLC6A3 40 bp VNTR 9-absent 275 51.2% 0.998 164 56.2% 0.928 0.092 0.78 (0.59–1.04)
9-present 262 48.8% 128 43.8%
intron 8 VNTR 2-absent 343 63.3% 0.852 195 64.8% 0.108 0.664 0.94 (0.70–1.26)
2-present 199 36.7% 106 35.2%
HWE: p value of deviation from Hardy-Weinberg equilibrium.
OR: Odds ratio, CI: confidence interval.
*significant after Bonferroni correction: p,0.0045 (0.05/11) for 11 tests.
doi:10.1371/journal.pone.0066592.t001
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out using NlaIII restriction enzyme. In case of DRD2 we had three
SNP-RFLP polymorphisms: the TaqIA (DRD2/ANKK1), TaqIB
and TaqID. For PCR we used the same method with specific
primer pairs. TaqIA: forward: 59-CCG TCG ACG GCT GGC
CAA GTT GTC TA-39, reverse: 59-CCG TCG ACC CTT CCT
GAG TGT CAT CA-39. TaqIB: forward: 59-GAT ACC CAC
TTC AGG AAG TC-39, reverse: 59-GAT GTG TAG GAA TTA
GCC AGG-39. TaqID: forward: 59-CCC AGC AGG GAG AGG
GAG TA-39, reverse: 59-GAC AAG TAC TTG GTA AGC ATG-
39. For the genotype dependent digestion 1x TaqI Buffer, 2.5 U
Taq restriction enzyme, 5 mL PCR product supplemented with
distilled water to reach the final volume of 10 mL. Digestions were
performed during a 65uC overnight incubation followed by a
fragment separation on 2.5% agarose gel matrix.
2.2. Allele-Specific Amplification (ASA). In the case of
COMT we used an ASA by tetra-primer PCR. A pair of flanking
primers (1: 59-TGC TCA CCT CTC CTC CGT-39, 2: 59-ACA
CCC ATA CAA GCA TTC ATC-39) and two internal primers (1:
59-CAC ACC TTG TCC TTC AC-39, 2: 59 TGG TGG ATT
TCG CTG GCA 39).
DRD4 –521 C/T genotypes were also determined by ASA.
Flanking primers are the following: 59-GGA ATG GAG GAG
GGA GCG GG-39; 59-CGC TCC ACC GTG AGC CCA GTA
T-39. Internal specific primers: 59-GGA GCG GGC GTG GAG
GGC-39; 59-GCC TCG ACC TCG TGC GCA-39. Same thing
with the 2616 C/G SNP. Flanking primers: 59-GAA CCT ACC
CCG GCC TGT CGT-39; 59-AGA CGG GAA TGA AGC GAG
GTG G-39. Internal primers: 59-TGG TCG CGG GGG CTG
AGC-39; 59-CCC CCC MGC AGC CTC TGG YC-39
(M = A+C, Y = C+T, degenerated nucleotides).
As for genotyping of the intron 8 VNTR of the DAT gene we
used a PCR-based method with forward (59-GCTTGGGGAAG-
GAAGGG-39) and reverse primers (59-
TGTGTGCGTGCATGTGG-39). The same method was used
for genotyping the DAT1 40 bp VNTR in the 39 untranslated
region of the gene: forward primer: 59-TGT GGT GTA GGG
AAC GGC CTG AG-39, reverse primer: 59-CTT CCT GGA
GGT CAC GGC TCA AGG-39. In the case of the VNTR
polymorphisms of the DRD4 gene: the 120 bp duplication
primers: forward primer: 59-GTT GGC TGT CTT TTC TCA
TTG TTT CCA TTG-39, reverse primer: 59-GAA GGA GCA
GGC ACC GTG AGC-39; the 48 bp VNTR primers: forward
primer: 59-GCG ACT ACG TGG TCT ACT CG-39, reverse
primer: 59-AGG ACC CTC ATG GCC TTG-39.
3. Statistical Analyses
Our case-control analysis applied a dominant model of minor
alleles, i.e. genotypes were grouped according to the presence or
the absence of the minor allele. For single marker analysis
genotype frequencies were compared by Chi-squared test, using
SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA). P-
values,0.05 were considered nominally significant. Correction for
multiple testing was made according to the stringent Bonferroni
correction: the threshold significance was adjusted to p,0.0045,
where 0.0045 = 0.05/11 (since 11 polymorphisms were tested).
Linkage disequilibrium between the ANKK1 and DRD2 SNPs
(TaqIA and TaqIB) was calculated by the HaploView program,
version 4.2. (Daly Lab, Cambridge, MA, USA) [61]. Haplotype
analyses were conducted by likelihood-based association analysis
using UNPHASED [62].
Besides standard association testing we performed a systems-
based association analysis, as well. A central concept in this
approach is strong relevance. A variable is strongly relevant if its
statistical association remains relevant given all the other variables,
i.e. its effect is not mediated by other variables [63]. This concept
can be generalized to multiple variables as follows. A set of
variables is sufficient as explanatory variables for a given target if
all the other variables are not statistically associated, i.e. if these
variables shield the target from the effect of the other variables
[64]. This set of variables X’ (a subset of all variables X) is called a
Markov blanket set (MBS(Y)) of variables with regard to target Y.
For a given variable/factor Xi, being a member of MBS is called
Markov blanket membership (MBM(Y, Xi)). The Bayesian
framework allows us to calculate the posterior probabilities of
these properties by performing a random walk over the set of
possible network structures using a Markov chain Monte Carlo
simulation. We used the method published earlier to calculate the
MBM and MBS posterior probabilities, with the following settings:
8*106 MCMC steps, 106 burn-in steps, 5 maximum parents,
Cooper-Herskovits prior (for the detailed description of the
approach, see [47]).
These posteriors offer a new way to quantify the interaction or
redundancy of the variable set {Xi1, …, Xin} over dataset D.
Redundancy shows us if the effect of a set of variables can be
accounted for by any of the variables in the set, while interaction
shows us effects, which are greater than the effect of the individual
variables. We computed the interaction and redundancy scores R
for pairs of predictors Xi, Xj with the following formula:
Ri,j~
P Xi,Xj(MBS Yð ÞD
 
P Xi(MBS Yð ÞDð Þ  P Xj(MBS Yð ÞD
 
By applying this method, we can see whether the differences of
R values from 1 indicate an interaction (R.1) or a redundancy
(R,1). The corresponding Interaction Ratio is then defined by
IR= ln(R), and the Redundancy Ratio by RR= -ln(R).
Results
1. Single Marker Analysis
A sample of 303 heroin dependent patients and 555 controls of
Central European descent were analyzed for 7 SNPs and 4
VNTRs of the dopaminergic system. Main characteristics of SNPs
and VNTRs studied in this work are summarized in Table 2 and
3, respectively. Table 2 shows the gene symbols, alternative
symbols, genomic coordinates, rs numbers and alternative names
of SNPs studied here. Minor allele frequencies (MAF) of our own
data are compared with data of mixed European population from
the ALFRED (The ALlele FREquency Database - http://alfred.
med.yale.edu/) database. Table 3 contains the basic properties of
the length polymorphisms possessing variable numbers of tandem
repeats (VNTRs) assessed in this study.
For testing the linkage disequilibrium (LD) among multiple
polymorphisms of DRD2 (Figure 1A) and DRD4 (Figure 1B)
genes the HaploView program was used. A strong LD was found
between the TaqIA and TaqIB (98%) in the DRD2 gene.
Interestingly, the linkage of the third studied DRD2 SNP (TaqID)
lying in between the strongly linked SNPs (TaqIA and TaqIB)
shows an ambiguous picture: it is linked strongly to TaqIB (98%)
but not to TaqIA (67%). The two adjacent SNPs in the DRD4
gene located in the promoter region with 615 and 616 bp
upstream of the start codon, are strongly linked (98%), as
expected. On the other hand, the 2521 C/T SNP has only a
weak linkage to the previous ones (47%).
Results of our single marker case-control analysis are listed in
Table 1. Both the common names and rs numbers of SNPs are
given for better understanding. The table shows the number of the
Association Study of Heroin Dependence
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individuals (N) and also the percentages (%) in each genotype
category for the control and for the heroin dependent (case)
sample. Observed genotype frequencies are consistent with Hardy-
Weinberg equilibrium (see the p values in column ‘‘HWE’’) in the
control group for all SNPs. In case of length polymorphisms
genotype categories were grouped according to the presence or
absence of the second most frequent allele and the HWE was
calculated for these categories. The complete list of the VNTR
genotypes including all the variants is shown in Table S1.
The frequentist calculation method of case-control analysis was
based on the presence or the absence of the minor allele (dominant
model), all p values showing nominal significance (p,0.05) are
seen in bold in Table 1. According to the data the minor (T) allele
containing genotypes (TT+CT) of TaqIA polymorphism
(rs1800497) in the ANKK1 gene were overrepresented in patients
(6.1%+34%) when compared to the controls (3.2%+27.9%)
suggesting a genetic effect of the T allele on heroin dependence
risk (p = 0.009). A similar effect was found for the strongly linked
TaqIB SNP (rs1079597) of the DRD2 gene: the minor A allele
containing genotypes were overexpressed among heroin depen-
dent patients (4.6%+31.3%) compared to the control group
(2.3%+23.5%, p = 0.003). As seen in Table 1, the odds ratios of
these polymorphisms are relatively high (1.49 and 1.61 for TaqIA
and TaqIB, respectively). Moreover, the –521 C/T polymorphism
of the DRD4 gene and heroin dependence also showed a nominal
association (p = 0.007). Although the two alleles have quite a
similar frequency, the minor C allele seems to have a protective
effect against heroin addiction as both CC and CT have a lower
frequency among heroin dependent patients (20.2%+44.4%) than
controls (21.0%+52.6%). No significant differences were found
between heroin dependent patients and controls in the other
polymorphisms included in this study. After applying the stringent
Bonferroni correction for multiple testing (p,0.0045 [0.05/11] for
the 11 tests), only the effect of the DRD2 TaqIB SNP remained
significant (labeled by an asterisk in Table 1) suggesting that the
presence of the DRD2 TaqIB minor allele is a strongly relevant
component in the genetic background of heroin dependence.
2. Multiple Marker Analysis
Since the Bonferroni correction is one of the stringent methods
for analyzing multiple comparison data, methods of multiple
marker analysis were also applied in order to avoid false negative
findings. As a first step, haplotype analysis was carried out for TaqI
polymorphisms in the DRD2/ANKK1 genes and the results are
presented in Table S2. Although we found nominally significant
associations of haplotypes TaqIA-TaqIB, TaqID-TaqIB and TaqIA-
TaqID-TaqIB (p = 0.0063, p = 0.0136, p = 0.028, respectively) with
heroin addiction, these results might be a simple consequence of
the strongly linked minor risk alleles.
The T,A haplotype of the two strongly linked minor alleles of
TaqIA and TaqIB SNPs was overrepresented in the case group
(19.9%) compared to controls (13.8%), suggesting the association
of T,A haplotype with heroin dependence (p = 0.0063). It should
be noted, however, that the total of the haplotype frequencies of
linked minor alleles (T,A: 13.8% in controls) and linked major
alleles (C,G: 82.9% in controls) is near 97%, and the other
haplotypes are extremely rare. Therefore, the association of T,A
haplotype with heroin dependence might be a direct consequence
of the associating minor alleles. Haplotype frequencies of DRD4
promoter SNPs were also calculated and compared between the
control and heroin dependent samples but no significant
differences were obtained (see: Table S3).
In an independent method for multiple marker analysis, we
applied a Bayesian network based Bayesian multilevel analysis
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(BN-BMLA) in order to evaluate dopaminergic risk factors of
heroin addiction. Using the same set of phenotype and genotype
data as in the above calculations, we summarized the results in a
consensus Bayesian network as seen in Figure 2. Our results
suggest significant effects of ANKK1 (TaqIA), DRD2 (TaqIB) and
DRD4 (–521 C/T) SNPs, which are consistent with the findings of
the single marker analysis without correction for multiple testing,
as seen earlier.
An additional interesting finding of the network analysis is the
effect of another DRD4 promoter polymorphism (2615 A/G),
which has an indirect effect on our target variable (heroin
dependence). According to our results, the effect of the 2615 A/G
polymorphism is manifested through another DRD4 polymor-
phism, the 2521 C/T. The combined effect of these SNPs was
also seen by classical statistical methods, as shown in Table 4. No
difference of the DRD4 2521 C/T genotype distribution was
observed in the presence of the 2615 G allele, while in the
absence of this allele a significant (p = 0.0013) effect of the 2521
C/T polymorphism was demonstrated. These data are in good
agreement with the indirect effect of the DRD4 2615 SNP shown
on Figure 2.
Another interesting finding in the Bayesian analysis is the more
pronounced effect of the TaqIB polymorphism compared to
TaqIA. According to the results of the network analysis there is a
strong redundant effect between the DRD2 and ANKK1 gene
polymorphisms (Redundancy Ratio of 1.201). This means that the
posterior probability of TaqIB or TaqIA being present alone in our
model is more than 3.32 times as likely as both of them being
present in the model. Our model yielded a higher posterior
probability of relevance for the DRD2 TaqIB (P = 0.67), than the
relevance of the ANKK1 TaqIA (P = 0.27) variants (Figure 3),
therefore the effect of the TaqIA seems to be negligible compared
to TaqIB. The probable multivariate models can be seen in
Figure 3 by starting from the left (1.0) empty model. Each step
from the root node of the dendrogram along the edges adds
another variable to the model. The P value under the name of
Table 3. Genetic variants of the dopaminerg system.
Length polymorphisms
Gene symbol and name**
Alternative
names
Chromosomal
location Genomic coordinates Repeat region In gene location
DRD4 Dopamine receptor D4 11p15.5 11:637,304–640,705 120 bp dup 1.2 kb upstream of the
initiation codon
48 bp VNTR exon 3
SLC6A3 Solute carrier
family 6
(neurotransmitter
transporter,
dopamine),
member 3
Dopamine transporter 1
(DAT1)
5p15.33 5:1,392,904–1,445,542 40 bp VNTR 39 UTR
intron 8 VNTR intron 8
**Approved symbol from the HUGO Gene Nomenclature Committee (HGNC) database.
VNTR =Variable number of tandem repeats.
doi:10.1371/journal.pone.0066592.t003
Figure 1. HaploView analysis of pairwise linkage disequilibrium in DRD2 and DRD4. Three marker SNPs are shown in both panel A for
DRD2 and panel B for DRD4. The colors represent the relative D’/LOD scores. Linkage disequilibria are displayed as pairwise D’ values multiplied by
100. Shading represents the magnitude and significance of pairwise LD on a grey-scale (black–high LD; white–low LD).
doi:10.1371/journal.pone.0066592.g001
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each node corresponds to the posterior probability of the model.
The Bayesian network (Figure 2) can be achieved in 3 steps on the
dendrogram. The detailed results of the Bayesian analysis are
shown in Figure S1 showing our findings including relevance,
redundancy and interaction of the studied polymorphisms.
Discussion
Genetic variants of the dopaminergic neurotransmitter system
as possible risk factors for heroin dependence have been
extensively studied but results are contradictory. The subtelomeric
region of chromosome 11p–where the DRD4 gene is located - was
identified in a genome-wide search for quantitative trait loci
influencing substance dependence vulnerability [65]. The DRD4
gene is rich in polymorphisms, including the one of the most
extensively studied 48 bp repeat polymorphism in exon 3 (48 bp
VNTR). Association of substance dependence and the 48 bp
VNTR was first proposed by Kotler et al. [66] and replicated by
others [67,68,69], but contradictory results were also obtained
[70,71,72]. Our data presented here did not show any tendency of
association between the 48 bp repeat and the risk of heroin
dependence in a cohort of 303 cases and 555 controls of Central
European descent. The promoter region of DRD4 is also highly
variable, including the 2521 C/T, the 2616 C/G SNP and the
2615 A/G variants described previously in our laboratory [42]. A
previous association study between the 2521 C/T polymorphism
and heroin abuse conducted on 387 Chinese subjects [72]
reported no significant difference of the 2521 C/T polymor-
phism, although their data showed a small, but non-significant
increase in frequencies of the 2521 C allele and CC genotype in
the injector subgroup. On the contrary, Lai and coworkers
demonstrated a higher T allele frequency among heroin depen-
dent patients (p = 0.0002) suggesting a higher preference for heroin
use in individuals with DRD4 2521 TT genotype [73]. This is in
good agreement with our present finding, which showed a nominal
significance (p = 0.007) of the2521 TT genotype as a risk factor of
heroin abuse. It also supports our results with heroin [74] and
nicotine dependence [75] published earlier, as well as a recent
study by others [76]. This effect of the 2521 C/T polymorphism
was no longer significant according to the frequentist model if
corrected for multiple testing. Haplotype analysis of the promoter
region did not yield any significant result either. On the other
hand, using the multivariate model implying a Bayesian multilevel
analysis we were able to confirm the association of 2521 C/T
polymorphism and heroin dependence, also demonstrating the
indirect effect of 2615 A/G. The presented results of the
multilevel analysis of the DRD4 promoter polymorphisms clearly
show the possible sources of contradictions obtained by the single
Figure 2. Posterior probabilities for variables in association with heroin use. In this graphic visualization each variable is represented by a
grey oval, while the target variable is the black oval. Variables are nodes in Bayesian networks. The arrows between nodes represent the direct
associations between variables; the thickness of the arrows reflects the posterior probability of the edge being present in the model. The DRD42615
A/G has no direct influence on the target variable, the effect is mediated through the DRD4 2521 C/T.
doi:10.1371/journal.pone.0066592.g002
Table 4. The combined effect of the DRD4 2615 A/G and 2521 C/T SNPs.
DRD4 2521 C/T p-value* OR** (95% CI)
C absent (TT) C present (CC,CT)
DRD4 -615 A/G G-absent (AA) control 114 21.9% 275 52.8% 0.0013 1.77 (1.25–2.50)
addict 91 30.3% 124 41.3%
G-present (AG,GG) control 23 4.4% 109 20.9% 1.0000 0.93 (0.45–1.93)
addict 14 4.7% 71 23.7%
*Pearson Chi-Square Exact Sig. (2-sided).
**OR: Odds ratio, CI: confidence interval.
doi:10.1371/journal.pone.0066592.t004
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marker approach, where interactions cannot be taken into
consideration. Association of 2521 C/T and Novelty Seeking, a
risk factor of drug addiction, was also demonstrated by others and
by our laboratory [77,78]. The replication studies of this
association were also contradictory as in most cases of single
marker analysis, but a meta-analysis provided further support for
the role of 2521 C/T in Novelty Seeking [79]. These previous
results seem to underline our positive findings on the 2521 C/T
SNP obtained by the Bayesian multilevel analysis rather than the
negative results when applying the single marker method with
correction for multiple testing.
The main results of our study are organized around the
dopamine D2 receptor and the neighboring ANKK1 gene,
encompassing the widely studied TaqIA polymorphism previously
thought to belong to the DRD2 gene. In a Spanish study [80] the
possible effect of the TaqIA polymorphism was examined in
methadone-treated substance dependent patients, who marked
heroin as their primary drug. Some of the subjects used other,
non-opioid substances besides heroin, however these were not
excluded from the study since DRD2 is potentially a non-specific
genetic predictor of substance use and dependence. This case-
control study reported a relationship between DRD2 and the
potential risk of developing heroin dependence. Based on the
results the A1A1 (rare) genotype of the TaqIA polymorphism is
associated with heroin dependence regardless of gender, however
the A1 allele showed association only in males. A Chinese study
(2009) carried out on Han Chinese subjects found that the
ANKK1 TaqI A1 allele carriers (genotypes A1A1 and A1A2) were
prone to heroin abuse in models of dominance or co-dominance
[10] in agreement with our findings. Results of association studies
between the TaqIA polymorphism and substance use disorder has
been summarized in a meta-analysis of Young et al (2004)
evaluating the results of 55 previous studies [81]. They concluded
that the A1 allele is a predictive marker of substance misuse and a
partial marker of severe substance use disorders. The statistical
power of this study was fairly strong at that time due to the sample
size of ten thousand, making it a robust meta-analysis. Here we
present a nominally significant association between the ANKK1
TaqIA SNP and heroin dependence (p = 0.009) which was no
longer valid after the stringent Bonferroni correction of multiple
testing. The negative finding between TaqIA and heroin depen-
dence was confirmed by our multilevel analysis, as well, supporting
the importance for multiple correction in this case.
Unlike the widely studied TaqIA, there are only a few
association studies with the TaqIB SNP, located in intron 1 of
the DRD2 gene and substance-related disorders. The possible role
of TaqIB was shown in nicotine addiction [82], cocaine-
dependence [83] and psychostimulant abuse [84], but significant
association with heroin dependence has not been published so far
to the best of our knowledge. According to our single marker
analysis presented here the TaqIB SNP is the only dopaminergic
polymorphism, which remained significant (p = 0.003) after
Bonferroni correction. Our multilevel analysis gave similar results,
demonstrating that the TaqIB SNP of DRD2 gene has the highest
level of relevance to heroin abuse, while a high redundancy or low
relevance was found for the TaqIA SNP (Figure 3), a polymor-
phism in the neighboring gene, which is strongly linked to the
studied DRD2 SNP. Based on these results we hypothesized that it
is rather a DRD2 than an ANKK1 gene variant which has a direct
effect on heroin dependence. One of the limitations of our study is
that we assessed only two SNPs (TaqIB and TaqID) of the DRD2
gene. A higher resolution linkage study might be necessary to
reveal the functional variants of this very important receptor gene,
including the study of the exonic Ser311Cys variant [85] shown as
a risk factor for schizophrenia.
Genes playing a role in the transport (SLC6A3, or DAT1) and
in the catabolism of dopamine (COMT) also seemed to be
challenging candidate genes for heroin abuse. Two length
polymorphisms of SLC6A3 has been related to addictive behaviors
previously, an intronic (intron 8 VNTR) and a 40 bp VNTR
located in the 39UTR. A few studies found positive association
between the 40 bp VNTR and cocaine dependence [86], ADHD
[87] and alcoholism [88]. Here we did not find any positive
relationship between either the 40 bp VNTR or the intron 8
Figure 3. Dendrogram of sub-relevant sets of SNPs. This relevance tree shows the hierarchy of relevant variable subsets. Starting from left to
right, paths starting from the (1.0) node show us the relevance of the subset of variables along the path. The respective posterior probability is shown
in the lower part of the end node. The posterior probability of DRD4 2521 and DRD 2615 both being relevant variables is 0.51. The posterior
probability decreases when increasing the number of variables (nodes) in the model. The TaqIA polymorphism only enters the model when TaqIB is
not present, signifying its redundancy.
doi:10.1371/journal.pone.0066592.g003
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VNTR of the SLC6A3 gene, with any of our calculation methods.
The COMT exonic variant (Val158Met) has been associated with
various psychiatric disorders (for a review see: Hosak, 2007 [89]),
but no positive findings were obtained here with heroin abuse
either with single marker or with multilevel analysis.
As all genetic association studies, the present one also has its
limitations. Type I error of false positive results might arise from
the relatively small sample size and from population heterogeneity.
Our Hungarian sample seems to be homogeneous, where the
genotype frequencies in the control group correspond to Hardy-
Weinberg equilibrium (see: Table S1). Although family-based
analyses are often preferred in order to avoid population
stratification, but this approach is more difficult in case of subjects
with substance abuse as many of these patients are not in touch
with their families. Trying to recruit and searching for patients
with complete and co-operating families might result in a drop out
of the most serious cases, thus distorting the results [90]. A further
limitation of our study is that the history of drug use was collected
from self-reported data without any urine test for drugs.
Additionally, we did not exclude cigarette smokers from our study
since there is a high rate of smoking among heroin dependent
patients despite the fact that the ANKK1 TaqIA A1 allele has been
associated with smoking [91,92]. Therefore, replications on other
homogenous populations, as well as extended studies using a larger
number of subjects would be necessary to further confirm the role
of the 2521 C/T, TaqIA and TaqIB polymorphisms in substance
dependence.
Although numerous groups studied the individual effects of the
dopaminergic candidate genes, little effort was done so far to
reveal the interactions among these genetic variations. The main
advantage of our study is the complex approach of the
dopaminergic candidate genes applying multilevel analysis besides
the single-marker methods to identify interactions and further
contributing factors in the context of heroin dependence. As a
result, the applied Bayesian method confirmed the relevance of
DRD2 TaqIB SNP in heroin dependence and revealed a new
interaction partner in the DRD4 promoter, the 2615 A/G SNP
modulating through the 2521 C/T SNP. Further studies are in
progress to apply these models for other, non-dopaminergic
candidate genes of substance abuse.
Supporting Information
Figure S1 The summary of our findings. The results of the
BN-BMLA method are shown in the inner dark grey ring. The
height of the red columns corresponding to each variable
represents the probability that the variable is present in the
Markov blanket of the target variable. The variables are grouped
in the outer circle based on their respective genes. The
interconnections in the center show the interaction and redun-
dancy scores of the pairs of variables, where the edge thickness
shows the effect’s strength, while red corresponds to interactions,
and blue shows the redundancies.
(TIF)
Table S1 The complete list of the VNTR genotypes
including all DRD4 and DAT variants.
(XLS)
Table S2 Haplotype frequencies of the Taq SNPs in the
DRD2 gene.
(XLS)
Table S3 Haplotype frequencies of the DRD4 promoter
SNPs in controls and heroin dependent patients.
(XLS)
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